XAGE-1b cancer/testis antigen is a potential target for immunotherapy in prostate cancer.

摘要: Introduction: Gene-modified cell vaccines are now considered to be the best way achieve immunotherapy for a variety of cancers including prostate cancer (PCa). XAGE-1b is member cancer/testis antigen family which has demonstrated strong immunogenicity. We investigated whether an ideal target PCa immunotherapy. Materials and Methods: The recombinant eukaryotic expression vector pDisplay-XAGE-1b was constructed. Then transfected into Myc-CaP cells its immunogenicity in vitro studied. After transfection, Myc-CaP-XAGE-1b were injected FVB mice subcutaneously. Tumor growth periodically observed anti-tumor effect mechanism vivo further Results: correctly constructed by DNA sequencing restriction endonuclease digestion. successfully with gene immunofluorescence staining Western blot. exhibited increased IFN-γ secretion, decreased IL-6 secretion enhanced killing activity. grew slower XAGE-1b-modified than wild-type mice. High dendritic low myeloid-derived suppressor tumor tissues expressed XAGE-1b. Conclusions: transfection could significantly enhance cells. Therefore, may attractive antigen-specific PCa.